Viktoria Gavrilina / Shutterstock.com
Pluristem develops therapies using cells from the placenta that have been cultured in a unique way. LSIPR finds out how the company protects and nourishes its technologies.
Several years after scientists found a way to harvest stem cells efficiently from the placenta after birth, companies are turning to it increasingly as a source for cell-based therapies.
The organ that for nine months keeps both mother and baby healthy during pregnancy and which, further research suggests, also plays a role in their long-term health, is a rich source of stem cells.
However, so understudied is the placenta that the Maryland-based Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH) has announced a Human Placenta Project, an initiative aimed at “unlocking the secrets” of the one-pound (500g) organ.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at firstname.lastname@example.org.
If you have any technical issues please email tech support.
Pluristern; stem cells; cell-based therapies; NIH